COTXF (Coiled Therapeutics) Total Liabilities: $0.37 Mil (As of Dec. 2025)


COTXF Coiled Therapeutics PLC COTXF
21 GF Score
Price $0.15
! 4 Warning Signs
View Full Analysis

What is Coiled Therapeutics Total Liabilities?

Coiled Therapeutics COTXF 21 Total Liabilities is $0.37 Mil as of Dec. 2025. GuruFocus rates COTXF with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Coiled Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was $0.37 Mil.

Coiled Therapeutics's quarterly Total Liabilities increased from Dec. 2024 ($1.09 Mil) to Jun. 2025 ($1.23 Mil) but then declined from Jun. 2025 ($1.23 Mil) to Dec. 2025 ($0.37 Mil).

Coiled Therapeutics's annual Total Liabilities increased from Dec. 2023 ($0.75 Mil) to Dec. 2024 ($1.09 Mil) but then declined from Dec. 2024 ($1.09 Mil) to Dec. 2025 ($0.37 Mil).

Coiled Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Coiled Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coiled Therapeutics Total Liabilities Chart

Coiled Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
0.63 0.69 0.75 1.09 0.37

Coiled Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 1.46 1.09 1.23 0.37
COTXF
21GF Score
Coiled Therapeutics PLC COTXF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coiled Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Coiled Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.365+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.37

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=3.605-3.24
=0.37

Coiled Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.365+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.37

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=3.605-3.24
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.37 Mil mean?
Coiled Therapeutics (COTXF) has a Total Liabilities of $0.37 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Coiled Therapeutics and its competitors.
Is Coiled Therapeutics' Total Liabilities too high?
Coiled Therapeutics' current Total Liabilities is $0.37 Mil. Overall, Coiled Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Coiled Therapeutics' Total Liabilities compare to VRTX and REGN?
Coiled Therapeutics' Total Liabilities of $0.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Coiled Therapeutics and its competitors. Coiled Therapeutics's current Total Liabilities is $0.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coiled Therapeutics stock overvalued right now?
Coiled Therapeutics (COTXF) has a current Total Liabilities of $0.37 Mil. The current Total Liabilities is $0.37 Mil. Coiled Therapeutics' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Coiled Therapeutics (COTXF), the current Total Liabilities is $0.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coiled Therapeutics Business Description

Other Exchanges COIL:UK0AG0:Germany
Address 85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Coiled Therapeutics PLC principal activity of the Company is to develop pre-clinical next generation medicines focused on hard-to-treat cancers. The Group operated in the single business segment of biotechnology.
21GF Score

Get the complete analysis for COTXF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price